For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon
This article was originally published in The Pink Sheet Daily
A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.
You may also be interested in...
Celgene Looks To Longer Revlimid Duration In MM To Expand Revenue
At ASH, Celgene detailed the results of its MM-020 study for continuous use of Revlimid in newly diagnosed multiple myeloma patients. That’s just one of several treatment strategies that could significantly increase patient time on the drug – and Revlimid revenues.
Deals of the Week: Is Astex Settling For An Underpriced Buyout?
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
Fibrosis/Cancer Start-up Seeded By Celgene Begins To Take Shape
Bay City Capital will back the PharmAkea with a $10 million Series A financing. Celgene also holds an undisclosed equity stake in the new company, under a three-year, $35 million R&D funding agreement with options to extend the arrangement or acquire the firm.